• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ:REGN)

    781.46 +10.67 (+1.38%)
    Streaming Delayed Price Updated: 10:47 AM EST, Feb 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 173,498
    Open 760.91
    Bid (Size) 781.13 (80)
    Ask (Size) 783.75 (80)
    Prev. Close 770.79
    Today's Range 760.91 - 786.08
    52wk Range 476.49 - 821.11
    Shares Outstanding 91,779,465
    Dividend Yield 0.45%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
    From Society For Science
    Via GlobeNewswire

    Performance

    YTD
    +0.7%
    +0.7%
    1 Month
    +1.3%
    +1.3%
    3 Month
    +0.2%
    +0.2%
    6 Month
    +34.8%
    +34.8%
    1 Year
    +10.5%
    +10.5%

    More News

    Read More
    News headline image
    2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock? ↗
    Via Stocktwits
    Regeneron Pharmaceuticals (NASDAQ:REGN) Reports Q4 2025 Earnings Beat Amid Product Transition ↗
    Via Chartmill
    Topics Earnings
    News headline image
    1 No-Brainer Biotech Stock To Buy Today and Never Sell ↗
    Via The Motley Fool
    News headline image
    Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
    Via MarketMinute
    News headline image
    Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
    Via MarketMinute
    News headline image
    1 Healthcare Stock Worth Your Attention and 2 Facing Challenges
    Via StockStory
    Topics Stocks
    News headline image
    Regeneron Announces Investor Conference Presentations
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    The Great Reversal: Tariffs Ignite Goods Inflation as Services Cool in Latest PCE Data
    Via MarketMinute
    Topics Artificial Intelligence Economy World Trade
    News headline image
    Regeneron (REGN) Q1 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Supply Chain
    News headline image
    Regeneron (REGN) Q2 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Regeneron (REGN) Q4 2024 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Regeneron (REGN) Q3 2024 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    This $24 Million Buy Amid a 45% Stock Drop Signals Conviction in a High-Margin Data Business ↗
    Via The Motley Fool
    News headline image
    Regeneron (REGN) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    These S&P500 stocks that are showing activity before the opening bell on Friday. ↗
    Via Chartmill
    News headline image
    Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗
    Via Stocktwits
    News headline image
    Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025
    Via StockStory
    News headline image
    Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Regeneron Pharmaceuticals publicly traded?
    Yes, Regeneron Pharmaceuticals is publicly traded.
    What exchange does Regeneron Pharmaceuticals trade on?
    Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
    What is the ticker symbol for Regeneron Pharmaceuticals?
    The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
    What is the current price of Regeneron Pharmaceuticals?
    The current price of Regeneron Pharmaceuticals is 781.46
    When was Regeneron Pharmaceuticals last traded?
    The last trade of Regeneron Pharmaceuticals was at 02/27/26 10:47 AM ET
    What is the market capitalization of Regeneron Pharmaceuticals?
    The market capitalization of Regeneron Pharmaceuticals is 71.72B
    How many shares of Regeneron Pharmaceuticals are outstanding?
    Regeneron Pharmaceuticals has 72B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.